<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109863</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000426431</org_study_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>CO04601</secondary_id>
    <secondary_id>NCI-6304</secondary_id>
    <secondary_id>H-2004-0396</secondary_id>
    <secondary_id>NCI-2009-00051</secondary_id>
    <secondary_id>A533300</secondary_id>
    <secondary_id>R01CA032685</secondary_id>
    <secondary_id>SMPH\HUMAN ONCOLOGY\HUMAN ONCO</secondary_id>
    <nct_id>NCT00109863</nct_id>
  </id_info>
  <brief_title>Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma</brief_title>
  <official_title>Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate&#xD;
      the immune system in different ways and stop tumor cells from growing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works&#xD;
      in treating patients with advanced melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical antitumor activity of hu14.18-interleukin-2 fusion protein in&#xD;
           patients with advanced melanoma.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the adverse events in patients treated with this drug.&#xD;
&#xD;
        -  Determine the in vivo immunologic activation in patients treated with this drug.&#xD;
&#xD;
        -  Determine the induction of anti-hu14.18 and anti-interleukin-2 antibodies in patients&#xD;
           treated with this drug.&#xD;
&#xD;
        -  Determine tumor antigen recognition by this drug in select patients with cutaneous&#xD;
           metastatic tumors, as measured by binding of the drug to the cutaneous metastatic tumor&#xD;
           and microscopic changes (including immune cell density and phenotype) of the tumor&#xD;
           tissue.&#xD;
&#xD;
      OUTLINE: Patients receive hu14.18-interleukin-2 fusion protein IV over 4 hours on days 1-3.&#xD;
      Treatment repeats every 28 days for 2 courses in the absence of symptomatic disease&#xD;
      progression or unacceptable toxicity. Patients then undergo disease reassessment. Patients&#xD;
      with an objective partial or complete clinical response or stable disease receive 2&#xD;
      additional courses of treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 7-15&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate and duration of response by clinical exam and radiology studies after every 2 courses</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events by clinical assessment daily during treatment and weekly after completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic activation induced by hu14.18-interleukin-2 after every 2 courses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of anti-idiotypic antibodies on days 1, 3, 4, and 8 of each course</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Hu14.18-IL2 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hu14.18-IL2 fusion protein</intervention_name>
    <arm_group_label>Hu14.18-IL2 Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant melanoma&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  Measurable disease by clinical assessment or imaging&#xD;
&#xD;
          -  No known standard curative therapy exists&#xD;
&#xD;
               -  Disease no longer controlled by surgery, chemotherapy, or radiotherapy&#xD;
&#xD;
          -  No clinically detectable pleural effusion or ascites&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,500/mm^3 OR&#xD;
&#xD;
          -  Granulocyte count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2 times normal&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No clinical evidence of hepatitis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No ischemic cardiac disease, congestive heart failure, or myocardial infarction within&#xD;
             the past 6 months&#xD;
&#xD;
          -  No uncontrolled cardiac rhythm disturbance&#xD;
&#xD;
          -  No myocardial ischemia or heart failure by exercise radionuclide scan for patients&#xD;
             with a history of cardiac disease, significant risk factors for coronary artery&#xD;
             disease, or ≥ 65 years of age&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Pulmonary function normal by exercise radionuclide scan for patients with a history of&#xD;
             cardiac disease, significant risk factors for coronary artery disease, or ≥ 65 years&#xD;
             of age&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No known hypersensitivity to the study drug, Tween-80®, or human immunoglobulin&#xD;
&#xD;
          -  No uncontrolled active infection&#xD;
&#xD;
        Neurologic&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No objective peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No clinically significant neurologic deficit&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must consent to the placement of a central venous line OR demonstrate stable&#xD;
             peripheral IV access&#xD;
&#xD;
          -  Must be willing and able to discontinue antihypertensive medications (if advised to do&#xD;
             so) on the days of study drug infusion&#xD;
&#xD;
          -  No uncontrolled active peptic ulcer&#xD;
&#xD;
          -  No known grade 4 side effects related to prior interleukin-2&#xD;
&#xD;
          -  No diabetes mellitus that has required systemic therapy (e.g., oral hypoglycemic&#xD;
             agents or insulin) within the past 3 months&#xD;
&#xD;
          -  No other significant illness&#xD;
&#xD;
          -  No significant psychiatric disability&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior monoclonal antibodies for biologic therapy, tumor imaging, purging of autologous&#xD;
             bone marrow/stem cells for re-infusion, or for any other reason allowed provided there&#xD;
             is documented absence of detectable antibody to hu14.18 by serology&#xD;
&#xD;
          -  No concurrent growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No immediate requirement for palliative chemotherapy&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 2 weeks since prior and no concurrent corticosteroids (e.g., dexamethasone)&#xD;
&#xD;
          -  No immediate requirement for palliative hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No immediate requirement for palliative radiotherapy&#xD;
&#xD;
               -  Concurrent palliative radiotherapy to localized painful lesions allowed provided&#xD;
                  ≥ 1 measurable or evaluable lesion is not irradiated AND the irradiated lesion is&#xD;
                  not used to assess tumor response&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 weeks since prior major surgery&#xD;
&#xD;
          -  No prior organ allografts&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since other prior and no concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No prior standard or experimental systemic therapy for stage IV melanoma&#xD;
&#xD;
          -  No concurrent myelosuppressive antineoplastic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R. Albertini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://cancer.wisc.edu</url>
    <description>University of Wisconsin Carbone Cancer Center</description>
  </link>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

